Correlation of the triglyceride-glucose index with major adverse cardiovascular events in type 2 diabetes mellitus patients with acute myocardial infarction combined with HFpEF

Correlation of the triglyceride-glucose index with major adverse cardiovascular events in type 2 diabetes mellitus patients with acute myocardial infarction combined with HFpEF

AimsThis study was conducted to evaluate the correlation between triglyceride-glucose index (TyG) and major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and heart failure with preserved ejection fraction (HFpEF) after acute myocardial infarction (AMI).Methods...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaodong Zhang, Nan Niu, Shengqin Yu, Xinxin Zhang, Xuefu Chen, Ming Yu, Wenmiao Zhang, Ying Liu, Zhenwei Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Endocrinology
Subjects:	triglyceride-glucose index acute myocardial infarction heart failure with preserved ejection fraction major adverse cardiovascular events type 2 diabetes mellitus
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1585067/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Inter‐atrial block as a predictor of adverse outcomes in patients with HFpEF
by: Jerremy Weerts, et al.
Published: (2025-06-01)

Cardiometabolic Phenotype in HFpEF: Insights from Murine Models
by: Ekaterina Ogurtsova, et al.
Published: (2025-03-01)

The correlation between lipoprotein(a) and major adverse cardiovascular events in patients with acute myocardial infarction combined with heart failure with preserved ejection fraction
by: Xiaodong Zhang, et al.
Published: (2025-06-01)

Diagnostic and therapeutic practice for HFpEF across continents and regions: An international survey
by: Inga J. Ingimarsdóttir, et al.
Published: (2025-02-01)

Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF
by: Xiao Li, et al.
Published: (2025-02-01)

Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF
by: Katherine L. Dominic, et al.
Published: (2024-12-01)

Targeting atrial fibrillation in HFpEF: the emerging role of pulsed field ablation
by: A. S. Parwani, et al.
Published: (2025-07-01)

The contribution of a short electrocardiographic diastolic interval to diastolic dysfunction and HFpEF
by: A. M. L. N. van Ommen, et al.
Published: (2025-05-01)

Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF
by: Lijun Song, et al.
Published: (2025-01-01)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
by: M. A. Manukyan, et al.
Published: (2021-11-01)

Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF
by: Patrick A. Kwaah, MBChB, et al.
Published: (2025-07-01)

A predictive model for heart failure with preserved ejection fraction following acute myocardial infarction: the HFpEF-AMI score
by: Xi Wu, et al.
Published: (2025-07-01)

Microvascular dysfunction across organs in heart failure with preserved ejection fraction: the PROSE-HFpEF case-control study
by: Jerremy Weerts, et al.
Published: (2025-07-01)

Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features
by: Melissa Herwig, et al.
Published: (2025-05-01)

Dysregulated inflammation, oxidative stress, and protein quality control in diabetic HFpEF: unraveling mechanisms and therapeutic targets
by: Simin Delalat, et al.
Published: (2025-05-01)

A two‐phase approach to identifying HFpEF in heart failure patients: Risk score evaluation and decision tree development
by: Izabella Uchmanowicz, et al.
Published: (2025-08-01)

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
by: Shenghua Zhou, et al.
Published: (2025-03-01)

Differences in Pulmonary Artery Flow Hemodynamics Between PAH and PH‐HFpEF: Insights From 4D‐Flow CMR
by: Bong‐Joon Kim, et al.
Published: (2025-01-01)

Targeted Overexpression of Mitochondrial ALDH2 in Coronary Endothelial Cells Mitigates HFpEF in a Diabetic Mouse Model
by: Guodong Pan, et al.
Published: (2025-07-01)

Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
by: Lingyun Luo, et al.
Published: (2025-04-01)

Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF
by: Zhen-Yu Yang, et al.
Published: (2025-08-01)

Semaglutide: an emerging treatment option for patients with obesity related HFpEF
by: Sanya Ashraf Khaskheli, et al.
Published: (2024-08-01)

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
by: Xiangling Duan, et al.
Published: (2025-04-01)

Prognosis of early‐stage HFpEF in the community‐dwelling elderly: The Northern Shanghai Study
by: Weilun Meng, et al.
Published: (2025-02-01)

V02max Determinants Are Associated With Different Cognitive Outcomes in Women With HFrEF and HFpEF
by: C. Gagnon, et al.
Published: (2025-06-01)

Alterations of myocardial ketone metabolism in heart failure with preserved ejection fraction (HFpEF)
by: Qiuyu Sun, et al.
Published: (2025-08-01)

Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning
by: Muyashaer Abudurexiti, et al.
Published: (2025-04-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice
by: Ke Zhang, et al.
Published: (2025-02-01)

Triglyceride-glucose index: a novel predictor of major adverse cardiovascular events and cerebrovascular events in patients with acute ST-segment elevation myocardial infarction
by: Ruibin Wei, et al.
Published: (2025-05-01)

Association of serum potassium time in target range with cardiovascular outcomes in patients with HFpEF
by: Yu Liu, et al.
Published: (2025-08-01)

Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design
by: Prithwish Banerjee, et al.
Published: (2019-11-01)

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis
by: Mingzhi Lin, et al.
Published: (2025-05-01)

Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation
by: Yanhua Yang, et al.
Published: (2020-01-01)

The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF)
by: Piotr Gajewski, et al.
Published: (2025-06-01)

Sex differences in the association between nutritional status and in‐hospital mortality in HFpEF patients
by: Michał Czapla, et al.
Published: (2025-08-01)

Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies
by: Francesca Coppi, et al.
Published: (2025-06-01)

The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
by: Francesca Cinti, et al.
Published: (2025-05-01)

Sex‐related pathophysiological mechanisms may be present before symptoms of HFpEF develop
by: B. Wong, et al.
Published: (2025-06-01)

Schaftoside improves HFpEF through regulation the autophagy-lysosome pathway by allosterically targeting CaMKII-δ
by: Haiying Zhang, et al.
Published: (2024-12-01)